Syneos and Komodo Launch “Lab to Life”
Syneos Health has announced that it has expanded its relationship with Komodo Health. The expanded partnership builds on two-years of previous collaboration between Syneos Health and Komodo Health, which began with data-driven strategies to enhance customer engagement for the Syneos Health Kinetic team. This will allow Syneos Health to analyze clinical, real-world, and commercial data, offering customers integration to their operational trial designs and commercialization deployment strategies.
Syneos Health will use Komodo Health’s Prism software to support feasibility, market sizing, site selection and patient cohort analytics. Additionally, Komodo’s Sentinel solution will provide a comprehensive view into real-world patient journeys and enable the integration of proprietary datasets, tools and algorithms to derive insights.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Oveporexton Shows Superior Efficacy in Phase II Narcolepsy Type 1 Trial Without Hepatotoxicity
May 16th 2025In the TAK-861-2001 Phase IIb study, oveporexton significantly improved wakefulness, daytime sleepiness, and cataplexy frequency in patients with narcolepsy type 1, outperforming current therapies and avoiding liver toxicity seen with earlier OX2R agonists, according to results published in The New England Journal of Medicine.
